Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Autor: Joshua J Solomon, Sonye K Danoff, Felix A Woodhead, Shelley Hurwitz, Rie Maurer, Ian Glaspole, Paul F Dellaripa, Bibek Gooptu, Robert Vassallo, P Gerard Cox, Kevin R Flaherty, Huzaifa I Adamali, Michael A Gibbons, Lauren Troy, Ian A Forrest, Joseph A Lasky, Lisa G Spencer, Jeffrey Golden, Mary Beth Scholand, Nazia Chaudhuri, Mark A Perrella, David A Lynch, Daniel C Chambers, Martin Kolb, Cathie Spino, Ganesh Raghu, Hilary J Goldberg, Ivan O Rosas, Shana Haynes-Harp, Fernando Poli, Coimbatore Sree Vidya, Rebecca R. Baron, Timothy Clouser, Tracy Doyle, Anthony Maeda, Kristin B. Highland, Jemima F. Albayda, Sarah E. Collins, Karthik S. Suresh, John M. Davis, Andrew H. Limper, Isabel Amigues, Kristina Eliopoulos, Jeffery J. Swigris, Stephen Humphries, John C. Huntwork, Chris Glynn, Steve R. Duncan, Maria I. Danila, Marilyn K. Glassberg, Elana M. Oberstein, Elizabeth A. Belloli, Linda Briggs, Vivek Nagaraja, Linda Cholewa, Donna DiFranco, Edward Green, Christie Liffick, Tanvi Naik, Genevieve Montas, Dorota Lebiedz-Odrobina, Reba Bissell, Mark Wener, Lisa H. Lancaster, Leslie J. Crawford, Karmela Chan, Robert J. Kaner, Alicia Morris, Xiaoping Wu, Nader A. Khalidi, Christopher J. Ryerson, Alyson W. Wong, Charlene D. Fell, Sharon A. LeClercq, Mark Hyman, Shane Shapera, Shikha Mittoo, Shireen Shaffu, Karl Gaffney, Andrew M. Wilson, Shaney Barratt, Harsha Gunawardena, Rachel K. Hoyles, Joel David, Namrata Kewalramani, Toby M. Maher, Philip L. Molyneaux, Maria A. Kokosi, Matthew J. Cates, Mandizha Mandizha, Abdul Ashish, Gladstone Chelliah, Helen Parfrey, Muhunthan Thillai, Josephine Vila, Sophie V. Fletcher, Paul Beirne, Clair Favager, Jo Brown, Julie K. Dawson, Pilar Rivera Ortega, Sahena Haque, Pippa Watson, Jun K. Khoo, Karen Symons, Peter Youssef, John A. Mackintosh

Publikováno v: The Lancet. Respiratory medicine.

Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b218402ab90005851b95898869a5c8b4
https://pubmed.ncbi.nlm.nih.gov/36075242

Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety

Autor: CLAIRE BOMBARDIER, GLEN S. HAZLEWOOD, POONEH AKHAVAN, ORIT SCHIEIR, ANNE DOOLEY, BOULOS HARAOUI, MAJED KHRAISHI, SHARON A. LECLERCQ, JEAN LÉGARÉ, DIANNE P. MOSHER, JAMES PENCHARZ, JANET E. POPE, JOHN THOMSON, CARTER THORNE, MICHEL ZUMMER, MICHAEL A. GARDAM, JOHAN ASKLING, VIVIAN BYKERK

Publikováno v: The Journal of rheumatology. 39(8)

Objective.The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part II, focus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486c1bd503943b25d76e61d0d1c27ac0
https://pubmed.ncbi.nlm.nih.gov/22707613